Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Leases (2020 - 2025)

Revolution Medicines (RVMD) has 6 years of Current Leases data on record, last reported at $16.5 million in Q4 2025.

  • For Q4 2025, Current Leases rose 27.94% year-over-year to $16.5 million; the TTM value through Dec 2025 reached $16.5 million, up 27.94%, while the annual FY2025 figure was $16.5 million, 27.94% up from the prior year.
  • Current Leases reached $16.5 million in Q4 2025 per RVMD's latest filing, up from $13.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $16.5 million in Q4 2025 and bottomed at $3.7 million in Q1 2021.
  • Average Current Leases over 5 years is $8.7 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Current Leases: rose 8.8% in 2023, then soared 74.68% in 2024.
  • A 5-year view of Current Leases shows it stood at $6.2 million in 2021, then increased by 9.0% to $6.8 million in 2022, then grew by 8.8% to $7.4 million in 2023, then skyrocketed by 74.68% to $12.9 million in 2024, then grew by 27.94% to $16.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $16.5 million in Q4 2025, $13.1 million in Q2 2025, and $13.0 million in Q1 2025.